Coppell Advisory Solutions LLC Sells 2,556 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Coppell Advisory Solutions LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,042 shares of the biopharmaceutical company's stock after selling 2,556 shares during the quarter. Coppell Advisory Solutions LLC's holdings in Gilead Sciences were worth $3,224,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Nicolet Advisory Services LLC grew its stake in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after purchasing an additional 100 shares during the last quarter. Southland Equity Partners LLC lifted its stake in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 110 shares during the period. Berkshire Bank lifted its position in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 111 shares during the period. CFO4Life Group LLC raised its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after purchasing an additional 112 shares during the period. Finally, Howe & Rusling Inc. boosted its holdings in Gilead Sciences by 2.5% in the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after acquiring an additional 115 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 2.8 %

GILD stock traded down $2.98 during midday trading on Friday, hitting $103.17. The company had a trading volume of 14,207,970 shares, compared to its average volume of 7,506,787. The stock has a market cap of $128.46 billion, a price-to-earnings ratio of 278.84, a PEG ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's 50 day moving average price is $109.21 and its 200 day moving average price is $98.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the previous year, the firm earned ($1.32) earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.06%. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GILD. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $109.43.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,540,875 in the last quarter. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.